Developer docs
API playgroundTry for free, no card

Search company profiles

Greenoaks

Full company profile

uuid0000hm7

Namestring
Greenoaks
Legal namestring
Greenoaks LLC
Websiteurl
greenoaks.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Greenoaks is a privately held San Francisco-based investment firm (Greenoaks LLC) founded by Neil Mehta, operating as a global venture capital and growth equity investor in technology companies. The firm deploys capital across stages from seed through growth equity into a concentrated set of verticals — predominantly AI (Anthropic, Sierra, Cyera, WorkOS, Nava, Pax, Mind Robotics, Glow), enterprise software and fintech (Revolut, Brex), biotech and healthcare (NewLimit, Alan, Vetic), and emerging tech such as micromobility (ALSO, a Rivian spin-out) and industrial robotics (Mytra). Geographic footprint spans the United States, Canada, Europe (France, Belgium, Spain), the United Kingdom, Brazil, India, Singapore, and Israel, executed through a compact team of 11–50 employees led by Mehta, managing partner Benny Peretz, director of research Mac Steele, and principal Anlei Tang.

Greenoaks' business model is a standard venture capital structure: it raises capital from limited partners, invests into portfolio companies, and earns revenue through management fees on assets under management plus carried interest on profitable exits — neither figure is publicly disclosed. Pricing is therefore not applicable at the portfolio company level; rather, the firm writes checks ranging from sub-$50M seed rounds (Pax, Nava, Vetic) to multi-billion-dollar growth rounds (Anthropic $65B Series H, Revolut $75B secondary). The firm's go-to-market relies on founder relationships, institutional syndicate partnerships (Sequoia, Founders Fund, Altimeter, Dragoneer, Bessemer, Index, Tiger Global, GV, Coatue), and selective lead positions, with an unusually high frequency of co-lead or lead roles relative to its small headcount.

The firm has no proprietary technology products or disclosed AI/ML capabilities of its own; its platform is investment judgment, capital deployment capacity, and syndicate relationships. Notable infrastructure signals include a recent $10 million endowment gift from founder Neil Mehta to the Harker School for a student venture investment initiative, and reported fundraising activity for a separate $100M–$500M political endowment vehicle pitched to Silicon Valley billionaires, suggesting the firm is evolving beyond a pure fund-management model into adjacent influence and ecosystem-building activities.

Short descriptiontext

Greenoaks is a San Francisco-based private venture capital and growth equity firm founded by Neil Mehta that invests globally from seed to growth stage, concentrating on AI (Anthropic, Sierra, Cyera), enterprise software, fintech, biotech, and emerging technology companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investments, growth equity funding, technology investment firm, startup growth capital, private equity investments
Industry2 codes
PRIMARYFSANACAA
Technology & Software Growth Equity
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity
NAICS code1 code
  • All Other Financial Investment Activities52399
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital and Growth Equity Investment
Social media profiles1 record
Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Greenoaks is a private investment firm that deploys venture capital and growth equity into technology companies across multiple stages (seed through Series H) and sectors including AI, enterprise software, fintech, healthcare, biotech, cybersecurity, robotics, micromobility, and consumer technology. The firm invests as both lead and participating investor, deploying capital alongside institutional co-investors in major funding rounds globally.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Greenoaks is a venture capital investment firm that provides growth capital and investment services to technology companies. As an investment firm, Greenoaks does not offer a traditional product portfolio but rather deploys capital into portfolio companies across various sectors including AI, healthcare, fintech, and consumer technology.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthersAnnounced on2026-02-12
Description

Greenoaks founder Neil Mehta provided $10 million endowment gift to Harker School for Venture Investment Initiative enabling select seniors to make real investments in startups.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global venture and growth firm with strong European and US presence. Co-invested with Greenoaks in Alan's €100M round and Glow; comparable in stage breadth and global tech mandate.

TypeDirect peer
Description

Software-focused growth equity and venture firm. Comparable in stage breadth, technology orientation, and ability to deploy multi-hundred-million-dollar checks into growth-stage companies.

TypeDirect peer
Description

Technology-focused venture firm investing from seed through growth. Co-led NewLimit's Series C with Greenoaks; directly comparable as a deep-tech oriented investor writing multi-stage checks.

TypeDirect peer
Description

Major venture and growth firm investing across AI, enterprise software, fintech, and bio. Comparable to Greenoaks in stage breadth, sector focus on technology, and ability to write large growth-stage checks.

TypeDirect peer
Description

Multi-stage venture and growth firm investing across technology, healthcare, and fintech. Comparable in sector breadth and stage range (seed through growth).

TypeDirect peer
Description

Premier venture and growth equity firm investing across technology stages globally. Greenoaks repeatedly co-invests with Sequoia (Anthropic, Sierra, Cyera, Eon, Glow), making it the closest direct comparable in mandate and check size.

TypeDirect peer
Description

Technology-focused investment firm deploying capital across public and private markets. Co-led Anthropic's Series G alongside Greenoaks participation; highly comparable in growth-stage tech focus and willingness to write mega-checks.

TypeDirect peer
Description

Growth-stage technology investor known for large, fast deployments. Co-led Sierra's Series E alongside Greenoaks participation; directly comparable in late-stage tech check writing.

TypeDirect peer
Description

Technology-focused investment firm with growth equity mandate. Co-led Anthropic's $65B Series H with Greenoaks; directly comparable in mega-check growth-stage tech investing.

TypeDirect peer
Description

Growth-oriented technology investor frequently co-investing with Greenoaks (Anthropic Series H, Revolut secondary). Highly comparable in mandate and stage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment206 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Greenoaks

Venture Capital and Growth Equity Investmentgreenoaks.com

Greenoaks is a San Francisco-based private venture capital and growth equity firm founded by Neil Mehta that invests globally from seed to growth stage, concentrating on AI (Anthropic, Sierra, Cyera), enterprise software, fintech, biotech, and emerging technology companies.

What Greenoaks does

Greenoaks is a privately held San Francisco-based investment firm (Greenoaks LLC) founded by Neil Mehta, operating as a global venture capital and growth equity investor in technology companies. The firm deploys capital across stages from seed through growth equity into a concentrated set of verticals — predominantly AI (Anthropic, Sierra, Cyera, WorkOS, Nava, Pax, Mind Robotics, Glow), enterprise software and fintech (Revolut, Brex), biotech and healthcare (NewLimit, Alan, Vetic), and emerging tech such as micromobility (ALSO, a Rivian spin-out) and industrial robotics (Mytra). Geographic footprint spans the United States, Canada, Europe (France, Belgium, Spain), the United Kingdom, Brazil, India, Singapore, and Israel, executed through a compact team of 11–50 employees led by Mehta, managing partner Benny Peretz, director of research Mac Steele, and principal Anlei Tang.

Greenoaks' business model is a standard venture capital structure: it raises capital from limited partners, invests into portfolio companies, and earns revenue through management fees on assets under management plus carried interest on profitable exits — neither figure is publicly disclosed. Pricing is therefore not applicable at the portfolio company level; rather, the firm writes checks ranging from sub-$50M seed rounds (Pax, Nava, Vetic) to multi-billion-dollar growth rounds (Anthropic $65B Series H, Revolut $75B secondary). The firm's go-to-market relies on founder relationships, institutional syndicate partnerships (Sequoia, Founders Fund, Altimeter, Dragoneer, Bessemer, Index, Tiger Global, GV, Coatue), and selective lead positions, with an unusually high frequency of co-lead or lead roles relative to its small headcount.

The firm has no proprietary technology products or disclosed AI/ML capabilities of its own; its platform is investment judgment, capital deployment capacity, and syndicate relationships. Notable infrastructure signals include a recent $10 million endowment gift from founder Neil Mehta to the Harker School for a student venture investment initiative, and reported fundraising activity for a separate $100M–$500M political endowment vehicle pitched to Silicon Valley billionaires, suggesting the firm is evolving beyond a pure fund-management model into adjacent influence and ecosystem-building activities.

Greenoaks firmographics

Firmographics
Name
Greenoaks
Legal name
Greenoaks LLC
Website
https://greenoaks.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
Greenoaks is a San Francisco-based private venture capital and growth equity firm founded by Neil Mehta that invests globally from seed to growth stage, concentrating on AI (Anthropic, Sierra, Cyera), enterprise software, fintech, biotech, and emerging technology companies.
Ownership category
akta.pro rank

Greenoaks industry classification

Industry
Product category
Venture Capital and Growth Equity Investment
NAICS
All Other Financial Investment Activities (52399)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAA
Technology & Software Growth Equity
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity

Keywords

  • Venture capital investments
  • Growth equity funding
  • Technology investment firm
  • Startup growth capital
  • Private equity investments

Where Greenoaks is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Greenoaks business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Greenoaks product offering

Product offering

Core offering

Greenoaks is a private investment firm that deploys venture capital and growth equity into technology companies across multiple stages (seed through Series H) and sectors including AI, enterprise software, fintech, healthcare, biotech, cybersecurity, robotics, micromobility, and consumer technology. The firm invests as both lead and participating investor, deploying capital alongside institutional co-investors in major funding rounds globally.

Product overview

Greenoaks is a venture capital investment firm that provides growth capital and investment services to technology companies. As an investment firm, Greenoaks does not offer a traditional product portfolio but rather deploys capital into portfolio companies across various sectors including AI, healthcare, fintech, and consumer technology.

Differentiator

Problem solved

Functional benefit

Companies that use Greenoaks

Customer profile

Segments1 record

Ideal customer profiles1 record

Greenoaks technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Greenoaks partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Harker SchoolminorOthers · 12 February 2026Greenoaks founder Neil Mehta provided $10 million endowment gift to Harker School for Venture Investment Initiative enabling select seniors to make real investments in startups.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Greenoaks competitors and assessment

Company assessment

Direct peers

  • Index Ventures: Global venture and growth firm with strong European and US presence. Co-invested with Greenoaks in Alan's €100M round and Glow; comparable in stage breadth and global tech mandate.
  • Insight Partners: Software-focused growth equity and venture firm. Comparable in stage breadth, technology orientation, and ability to deploy multi-hundred-million-dollar checks into growth-stage companies.
  • Founders Fund: Technology-focused venture firm investing from seed through growth. Co-led NewLimit's Series C with Greenoaks; directly comparable as a deep-tech oriented investor writing multi-stage checks.
  • Andreessen Horowitz (a16z): Major venture and growth firm investing across AI, enterprise software, fintech, and bio. Comparable to Greenoaks in stage breadth, sector focus on technology, and ability to write large growth-stage checks.
  • General Catalyst: Multi-stage venture and growth firm investing across technology, healthcare, and fintech. Comparable in sector breadth and stage range (seed through growth).
  • Sequoia Capital: Premier venture and growth equity firm investing across technology stages globally. Greenoaks repeatedly co-invests with Sequoia (Anthropic, Sierra, Cyera, Eon, Glow), making it the closest direct comparable in mandate and check size.
  • Coatue Management: Technology-focused investment firm deploying capital across public and private markets. Co-led Anthropic's Series G alongside Greenoaks participation; highly comparable in growth-stage tech focus and willingness to write mega-checks.
  • Tiger Global Management: Growth-stage technology investor known for large, fast deployments. Co-led Sierra's Series E alongside Greenoaks participation; directly comparable in late-stage tech check writing.
  • Altimeter Capital: Technology-focused investment firm with growth equity mandate. Co-led Anthropic's $65B Series H with Greenoaks; directly comparable in mega-check growth-stage tech investing.
  • Dragoneer Investment Group: Growth-oriented technology investor frequently co-investing with Greenoaks (Anthropic Series H, Revolut secondary). Highly comparable in mandate and stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Greenoaks social profiles

Digital presence

Greenoaks financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Greenoaks leadership team

Management profile

Number of profiles

Profiles4 records

Greenoaks funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Greenoaks M&A and investment

M&A and investment

M&A

Investments206 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Greenoaks

What does Greenoaks do?

Greenoaks is a private investment firm that deploys venture capital and growth equity into technology companies across multiple stages (seed through Series H) and sectors including AI, enterprise software, fintech, healthcare, biotech, cybersecurity, robotics, micromobility, and consumer technology. The firm invests as both lead and participating investor, deploying capital alongside institutional co-investors in major funding rounds globally.

Is Greenoaks a public or private company?

Greenoaks is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Greenoaks founded?

Greenoaks was founded in 2013. It employs 51 to 100 people.

Where is Greenoaks based?

Greenoaks is headquartered in San Francisco, United States, in the North America region.

Who are Greenoaks's main competitors?

Direct peers on record are Index Ventures, Insight Partners, Founders Fund, Andreessen Horowitz (a16z), General Catalyst, Sequoia Capital, Coatue Management, Tiger Global Management, Altimeter Capital and Dragoneer Investment Group.

Does Greenoaks have an API?

No public API is recorded for Greenoaks.

What industry is Greenoaks in?

Greenoaks's product category is Venture Capital and Growth Equity Investment. Its primary akta.pro industry code is FSANACAA, Technology & Software Growth Equity, with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 52399 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PedailyGoogle AI Pharmaceuticals completes $5 billion financing: Major AI pharmaceutical companies enter an arms race stageIsomorphic Labs completed a $5 billion Series C financing led by Greenoaks and Sequoia, while Anew Labs raised 2 billion RMB. Both companies, emerging from Google DeepMind and ByteDance, are developing AI-driven drug pipelines, with Anew disclosing an oral small molecule inhibiting three IL-17 dimers.Quantum ZeitgeistIsomorphic Labs raises $5 Billion Series C with Greenoaks, Sequoia CapitalIsomorphic Labs raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital. The funding will support its IsoDDE drug design engine and advance therapeutic candidates toward clinical trials. The company aims to build global AI-led bioengineering infrastructure.The TelegraphBritish tech entrepreneur raises $5bn for AI drug discovery companySir Demis Hassabis raised $5bn for Isomorphic Labs, a British AI drug discovery company, in a Series C round led by Greenoaks Capital. The funding values the company at $50bn, making it Britain's most valuable AI firm, and will support clinical trials. The company has not yet produced a trial drug.NDTV ProfitCan AI Solve All Disease? DeepMind Co-Founder Demis Hassabis Just Raised $5 Billion To Find OutIsomorphic Labs, founded by DeepMind co-founder Demis Hassabis, raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital. The funding will accelerate its AI drug-design platform IsoDDE and move candidates toward clinical trials. The company must now prove its technology translates into effective medicines.BioPharma DiveAI drugmaker Isomorphic restocks with $5B fundraiseIsomorphic Labs raised $5 billion in a Series C financing led by Greenoaks and Sequoia Capital, with Alphabet participating. The London-based AI drugmaker will use the funds to move from developing AI models to bringing medicines to the clinic and expand into new biology.YahooAI drugmaker Isomorphic restocks with $5B fundraiseIsomorphic Labs raised $5 billion in a Series C financing led by Greenoaks and Sequoia Capital, with Alphabet participating. The London-based AI drugmaker will use the funds to move from developing AI models to bringing medicines to the clinic and expand into new biology.CNBCDemis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEOIsomorphic Labs, founded by Demis Hassabis, raised a $5 billion Series C co-led by Greenoaks and Sequoia Capital. The funds will support AI-driven drug design and development, with the company's first therapeutic programs aiming for clinical trials. Drug discovery startups raised a record $23.2 billion in 2026.BloombergSequoia, Greenoaks Lead Isomorphic Lab’s $5 Billion Funding RoundIsomorphic Labs raised $5 billion in a Series C funding round led by Sequoia Capital and Greenoaks, announced Tuesday. The AI drug-design company, backed by Alphabet's venture arms, also added Andreessen Horowitz and earlier investors Thrive Capital, GV, and CapitalG.36krAI Company Backed by Nobel Laureate Secures 33.3 Billion Yuan in Latest Financing RoundIsomorphic Labs, an AI drug R&D company founded by Demis Hassabis, raised $5 billion in a Series C financing round, oversubscribed. The funding, led by Greenoaks and HSG, brings total disclosed financing to $7.7 billion. The company plans to advance its oncology and immunology projects to clinical trials.Fortune IndiaHow Neil Mehta’s biggest bet is shaping Greenoaks’ India growth storyGreenoaks Capital Partners, founded by Neil Mehta, invested $228 million in Zetwerk Manufacturing across eight rounds, making it its largest India bet. Zetwerk listed in October at a valuation over Rs 31,000 crore, with Greenoaks holding a 17.81% stake. The fund expects further Indian investments in fintech and drone delivery.